Guardant Health, Inc. reported total revenue of $191.5 million for the third quarter of 2024, marking a 34% increase compared to the same period in 2023. The company's net loss for the quarter was $107.8 million, or $0.88 per share, with an adjusted loss of $0.45 per share.
The company raised its full-year 2024 revenue guidance to a range of $735 million to $740 million, up from the previous range of $715 million to $725 million. This updated guidance reflects a projected annual growth of 30% to 31% over 2023, driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds.
Guardant Health's oncology revenue grew 34% year-over-year to $180.1 million, fueled by a 24% increase in oncology test volume. The average selling price (ASP) for Guardant360 Liquid remained strong at approximately $3,000, and the company achieved its 2028 target for Guardant360 Tissue ASP years ahead of schedule.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.